Ideal Generic Pathway for patients with suspected Chronic Myeloid Leukaemia (CML)

Referral received in secondary care

Haematologist consultation

Is there evidence of Leukaemia?

No

Manage as appropriate and remove from cancer pathway

Yes

Bone Marrow & molecular tests taken

CML confirmed

Specialist MDT review of results, plan treatment and consider suitability for clinical trials

Discuss results with patient and agree treatment options

Targeted Therapy Tyrosine Kinase Inhibitors (TKI)

Long term monitoring of disease

Maximum wait (days)

First Seen

Provide information and appropriate level of psychological support throughout the patient journey

Allocate Clinical Nurse Specialist / Key Worker

Holistic assessment and rehabilitation consideration

Inform patient’s GP of Serious Diagnosis

See TYA pathway

Liaise and involve healthcare professionals as required

Inter Provider Transfer Network Best Practice

Decision to Treat

Consider referral to specialist fertility services

First Treatment

First Seen

7 days

Inter Provider Transfer Network Best Practice

21 days

Decision to Treat

28 days

First Treatment

59 days

Medical History

Physical Examination

Blood Test

Molecular Tests

Earliest Clinically Appropriate Date for commencement of subsequent treatment